The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
List view / Grid view
Scientists have developed brain organoids that recapitulate the head size of autism patients to study the condition as well as possible therapies.
Two drugs, Nefiracetam and PHA 543613, were able to return neuronal signalling to near normal in organoids derived from patients with the autism spectrum disorder, Rett syndrome.
The researchers suggest the regions they identified in their study could be targeted to improve dysfunctional behaviours associated with autism spectrum disorders, even in adults.
Researchers have revealed that the disruption of oligodendrocytes, which produce myelin, may be a cause of autism spectrum disorder, so presents a therapeutic target.
Scientists have shown that the mutated CUL3 gene, which is involved in the cell’s clearance of proteins, plays a role in the development of autism and schizophrenia in mice.
Crystal structure of the dopamine 2 receptor bound to an antipsychotic drug provides a much-needed discovery in the quest to create effective drugs with fewer side effects...